University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States
Location status: Recruiting
Location contact
Lindsey Hageman, MPH, CCRP
CONTACT
Noha Sharafeldin, MD, MSc, PhD
CONTACT
NCT Number: NCT03094026
A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured.
Interested in participating?
Request Info21 year and older
All sexes
Interventional
Not applicable
Birmingham, Alabama, 35233, United States
Location status: Recruiting
Lindsey Hageman, MPH, CCRP
CONTACT
Noha Sharafeldin, MD, MSc, PhD
CONTACT
The investigators propose using an "off-the-shelf" product - Lumosity (http://www.lumosity.com/) - an online cognitive training program, to address the cognitive impairment in outpatient HCT survivors. The program offers over 60 tasks in game-like format that cover the main cognitive domains: processing speed, working memory, and executive function. Training will involve a daily session of 5 training tasks for 12 weeks. Each time the patient is logged in for a session, a customized report will be generated by the Lumosity program to capture performance information.
Ideally, targeting the intervention and offering it specifically to those at highest risk (integrating clinical and genetic markers) would ensure efficacy. However, evidence is lacking on whether patients are receptive to communication of individual genetic information and whether provision of such results would lead to enhanced intervention response. To realize the high expectations of personalized medicine, patients' preferences and attitudes need to be thoroughly investigated especially as more information on genetic risk becomes available. The investigators will examine patients' genetic knowledge to determine whether factual knowledge of genetics is essential for understanding genetic risk and for informing treatment decision making in this patient population.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Computer-based online cognitive training program using the Lumosity cognitive training program.
Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
Time frame: 12 weeks
Number of participants completing the 12 week intervention
Time frame: Baseline to 12 weeks
Change in cognitive function will be measured using cognitive test scores at baseline and 12 weeks
Time frame: Baseline
Genetic factual knowledge will be measured using a 16-item survey on knowledge about genes, chromosomes, cells, and diseases and how different characteristics are inherited from parents.
Time frame: Baseline
Effect size of associations of sociodemographic characteristics such as age, gender, race/ethnicity, education and income levels with genetic factual knowledge of participants will be measured.
Time frame: baseline
Patient ratings will be collected on a 5 Likert scale survey questionnaire to examine importance of receiving information on genetic risk of cognitive impairment post-HCT.
Time frame: baseline
Patient ratings will be collected on a 5 Likert scale survey questionnaire to measure association of likelihood of genetic risk of cognitive impairment (low chance vs high chance) on intervention uptake.
Time frame: baseline
Patient ratings will be collected on a 5 Likert scale survey questionnaire to measure association of likelihood of genetic risk of cognitive impairment (low chance vs high chance) on intervention adherence.
Contact information is provided by the study sponsor or research team.
Lindsey Hageman, MPH
CONTACT
Noha M Sharafeldin, MD,MSc, PhD
CONTACT
University of Alabama at Birmingham
Other
Intervention Strategies to Improve Cognitive Functioning in Hematologic Cancer Survivors After Hematopoietic Cell Transplantation
Acronym: cTAG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05708716
Cognition Disorders, Cognitive Dysfunction
Birmingham, Alabama, United States
View Trial DetailsNCT07729969
Cancer, Cognition Disorders
Bilbao, Bizkaia, Spain
View Trial DetailsNCT07114458
Brain Diseases, Central Nervous System Diseases
Hamburg, Free and Hanseatic City of Hamburg, Germany
View Trial DetailsNCT07718321
Brain Diseases, Brain Injuries
Sant'Angelo dei Lombardi, AV, Italy
View Trial Details